Expression of p53, Bax and Bcl-2 proteins in hepatocytes in non-alcoholic fatty liver disease

Table 1 Clinical characteristics of patients with liver steatosis

Clinical characteristic	Grade of steatosis (% of steatosis hepatocytes)
	< 33%(groupI)	33%-66%(group II)	> 66%(group III)
n	24	35	25
BMI	28 kg/m2	30 kg/m2	32 kg/m2
Cholesterol (mmol/L) Trigliceryde (mmol/L)	5.50 ± 0.75 2.60 ± 1.27	5.99 ± 1.29 2.78 ± 1.44	6.80 ± 2.30 3.16 ± 1.11
Bilirubina (µmol/L)	11.97 ± 5.13bd	17.1 ± 6.84	27.36 ± 20.52
ALT (μkat/L)	0.84 ± 0.35bd	1.70 ± 1.12	1.67 ± 0.38
AST (μkat/L)	0.60 ± 0.33bd	1.19 ± 0.50	1.87 ± 1.80
ALP (μkat/L)	1.12 ± 0.27bd	1.72 ± 0.45	2.10 ± 0.92
GGT (μkat/L)	0.75 ± 0.33bd	2.61 ± 3.42d	5.06 ± 4.34
Total protein (g/L)	7.4 ± 04d	7.0 ± 0.5d	6.4 ± 0.5
Albumin (g/L)	4.5 ± 1.2d	4.0 ± 0.2d	3.4 ± 0.7

^bP < 0.01 vs group II,

^dP < 0.01 vs group III (non-parametrical Student^'s-t test).

Table 2 Percentage of hepatocytes containing pro- and antiapoptotic proteins depending on the stage of liver steatosis (mean ± SD, %)

	Total	GroupI	Group II	Group III
Bax NSH 1	59 ± 21	66 ± 15	52 ± 27	57 ± 19
Bax SH 2	68 ± 23	71 ± 21	63 ± 28	67 ± 18
p53 NSH 1	24 ± 12	18 ± 14d	21 ± 9 d	35 ± 9
p53 SH 2	22 ± 17	14 ± 18bd	20 ± 13d	33 ± 14
Bcl2 NSH 1	55 ± 26	77 ± 21bd	46 ± 20	49 ± 27
Bcl2 SH 2	44 ± 27	52 ± 37	42 ± 20	41 ± 24

¹Non-steatosed hepatocytes;

²Steatosed hepatocytes.

^bP < 0.01 vs group II,

^dP < 0.01 vs group III (non-parametrical Student’s-t test).

Table 3 Correlation of biochemical degree of liver damage and expression of pro- and anti-apoptotic proteins in hepatocytes with the stage of liver steatosis

	r
ALT	0.6b
AST	0.37b
ALP	0.55b
GGT	0.53b
Total protein	-0.54b
Albumines	-0.34b
Bax NSH1	NS3
Bax SH2	NS3
p53 NSH1	0.49b
p53 SH2	0.54b
Bcl2 NSH1	-0.43b
Bcl2 SH2	NS3

¹Non-steatosed hepatocytes;

²Steatosed hepatocytes;

³Non-statistical correlation.

^bP < 0.01 vs the stage of liver steatosis (non-parametrical Spearman test).